Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Second obesity collaboration underway
July 2019
SHARING OPTIONS:

INGELHEIM, Germany & HØRSHOLM, Denmark—Boehringer Ingelheim and Gubra have initiated a second collaboration and license agreement to develop novel poly-agonist peptides to treat obesity. Under the terms of the agreement, Gubra stands to receive up to €240 million in upfront and success-based development and commercialization milestones, with the potential for staggered up to double-digit royalties on worldwide net sales of any products that result from this deal.
 
Henrik Blou, CEO of Gubra, remarked, “We are very pleased to enter into a second collaboration and license agreement with Boehringer Ingelheim focusing on the treatment of obesity. It is important for Gubra to find strong partners for our proprietary research programs, and our first collaboration with Boehringer Ingelheim has shown that the strengths of both companies are nicely complementary. Joining forces on this novel research program has the potential to take obesity treatment to the next level to the benefit of patients around the world.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.